Duration of untreated negative symptoms and duration of active negative symptoms: Proof of concepts

Early Intervention in Psychiatry

Volumn 2, Issue 1, 2008, Pages 27-33

  Murphy, Brendan P ^a,b   Stuart, Antonia H ^c   Mcgorry, Patrick D ^c,d  

^a Recovery and Prevention of Psychosis Service   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

Duration; First episode; Measurement; Negative symptoms; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; EARLY DIAGNOSIS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MODELS, PSYCHOLOGICAL; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 54149105285     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2007.00053.x     Document Type: Article

References (35)

1. Nibuya M, Kanba S, Sekiya U et al. Schizophrophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 1995; 38: 50-6.
2. Meisenzahl EM, Frodl T, Zetsche T et al. Investigation of a possible diencephalic pathology in schizophrenia. Psychol Res 2002; 115: 127-35.
3. Andreasen NC, Rezai K, Alliger R et al. Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia. Arch Gen Psychiatry 1992; 49: 943-58.
4. Rao ML, Moller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. Neuropsychobiol 1994; 30: 160-72.
5. Coyle JT. Glutamate and schizophrenia. Beyond the dopamine hypothesis cellular and molecular neurobiology. Cell Mol Neurobiol 2006; 26: 363-82.
6. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991; 48: 239-46.
7. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991; 48: 978-86.
8. Mayerhoff DE, Loebel AD, Jose MJ et al. The deficit state in first-episode schizophrenia. Am J Psychiatry 1994; 151: 1417-22.
9. Bow-Thomas CC, Velligan DI, Miller AL, Olsen J. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychol Res 1999; 86: 131-42.
10. Dickerson FB, Ringel N, Parente F. Predictors of residential independence among outpatients with schizophrenia. Psychol Serv 1999; 50: 515-19.
11. Milev P, Ho B-C, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506.
12. Stahl SM. Positive findings for negative symptoms of schizophrenia: No longer untreatable? Acta Psychiatr Scand 2006; 114: 301-2.
13. Lieberman JA, Safferman Z, Pollack S et al. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-52.
14. Breier AF, Malhotra AK, Su TP et al. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, Parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999; 156: 294-8.
15. Breier A, Buchanan RW, Irish D, Carpenter WT Jr. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns. Psychol Serv 2000; 51: 1249-53.
16. Kane J, Marder SR, Schooler NR et al. Clozapine and haloperidol in moderately refractory schizophrenia. Arch Gen Psychiatry 2001; 58: 965-72.
17. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68.
18. Lecrubier Y, Azorin M, Bottai T et al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001; 44: 41-6.
19. Meltzer HY, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986; 6: 329-38.
20. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualisations. Schizophr Bull 1996; 22: 353-70.
21. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode Schizophrenia. Am J Psychiatry 1992; 149: 1183-8.
22. Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: Impact on 2-year outcome. Psychiatry Med 2004; 34: 277-84.
23. Harris MG, Henry LP, Harrigan SM et al. The relationship between duration of untreated psychosis and outcome: An eight-year prospective study. Schizophr Res 2005; 79: 85-93.
24. Murphy BP, Chung Y-C, Park T-W, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res 2006a; 88: 5-25.
25. Hafner H, Maurer K, Loffler W, Riecher-Roessler A. The influence of age and sex on the response and early course of schizophrenia. Br J Psychiatry 1993; 162: 80-6.
26. Hafner H, an der Heiden W. The course of schizophrenia in the light of modern follow-up studies: The ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl. 4): 14-30.
27. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res 2004; 68: 37-48.
28. Norman RM, Malla AK. Duration of untreated psychosis: A critical examination of the concept and its importance. Psychiatry Med 2001; 31: 381-400.
29. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia: Prediction and patterns of change. Arch Gen Psychiatry 1995; 52: 352-60.
30. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa, 1981.
31. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
32. Murphy BP, Stuart AH, Wade D, Cotton S, McGorry PD. Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: A pilot study. Hum Psychopharmacol 2006; 21: 511-17.
33. McGorry PD, Bell RC, Dudgeon PL, Jackson HJ. The dimensional structure of first-episode psychosis: An exploratory factor analysis. Psychiatry Med 1998; 28: 935-47.
34. First MB, Gibbon M, Spitzer RL, Williams JBW. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders - Research Version. New York: Biometrics Research Department, New York State Psychiatric Institute, 1996.
35. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis -The Comprehensive Assessment of At Risk Mental States (CAARMS). Aust N Z J Psychiatry 2005; 39: 964-71.